Effects of Telemonitoring and Telemedicine Service for Hypertensive Care (Smart-HTN)
Hypertension

About this trial
This is an interventional supportive care trial for Hypertension focused on measuring telemonitoring, usual care, telemedicine, telehealth, home care, Health Care Quality, Access, Evaluation
Eligibility Criteria
Inclusion Criteria:
- Male and female patients who are able to receive outpatient treatment from over 20 to under 70 years of age.- Over SBP 140mmHg without diabetes or renal failure
Patients who are taking more than one kind of any antihypertensive medications
- Systolic blood pressure (SBP) ≥ 140mmHg in patient with diabetes mellitus and renal disease or
- Systolic blood pressure (SBP) ≥ 130mmHg in patient without diabetes mellitus and renal disease
- Patients who are able to understand the purpose of this trial and to read and write
- Patients who are able to use Smart Care PC for this trial
- Patients who participate voluntarily and sign the informed consent
Exclusion Criteria:
- Patients with severe hypertension (mean of two seated SBP ≥200 mmHg) at screening visit blood pressure measurement.
- Patients with secondary hypertension.
- HbA1c>11%.
- Patients are currently being hospitalized or planning to hospitalize due to hypertension.
- Patients with severe renal disease (above 1.5 times the upper limit of normal serum creatinine levels).
- Patients with any severe liver disease including cirrhosis (AST or ALT: above 3 times the upper limit of normal).
- Patients who have been suffered cardiac infarction or severe coronary artery disease within 6 months, or with clinically significant congestive heart failure or heart valve defects.
- Patients with phthisis, autoimmune disease or connective tissue disease.
- Patients on medication therapies which may interfere with their blood pressure.
- Patients with known history of allergic reaction or contraindication to angiotensin II antagonists.
- Pregnant or lactating woman.
- Patients with known history of alcoholism, mental illness, or drug dependency.
- Patients who have participated in other study within 12 weeks prior to screening visit.
- Any clinically significant medical condition including neurologic disease, gastrointestinal disease or malignant tumor, etc., which may affect the test results, or any other medical condition which in the opinion of the investigator makes the patients unsuitable for participation in the trial.
Sites / Locations
- Keimyung University Dongsan Medical Center
- Yeungnam University Medical Center
- Yonsei University Health System
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Other
Telemonitoring group
Telemonitoring & Telemedicine group
Control group
The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)
The subjects who are assigned in the Telemonitoring & Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring & Telemedicine group take remote medical treatment through video telephone instead of visiting study site.
The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)